News and Resources

Dexpramipexole Kv 7 Company News
12.06.19

Knopp Biosciences Appoints Mark Kreston as Chief Commercial Officer

Discover this News
12.02.19

Knopp Biosciences and University of Leicester Announce Update on Planned Phase 2 Clinical Trial of Oral Dexpramipexole in Severe Eosinophilic Asthma

Discover this News
11.27.19

Knopp Biosciences to Present Data Characterizing Its Potassium Channel Activator Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting

Discover this News
09.26.19

Knopp Biosciences Receives NIH HEAL Grant to Discover and Advance Non-Opioid Treatment for Chronic Pain

Discover this News
09.25.19

Knopp Biosciences Receives Year 4 Renewal of NIH Blueprint Grant Award for Advancing the Kv7 Activator KB-3061 in a Rare Neonatal Epilepsy

Discover this News
09.13.19

Knopp Biosciences to Present Data Characterizing its Kv7 Technology Platform’s Potential for Delivering Precision Medicines to Treat Diverse Neurological and Smooth Muscle Diseases

Discover this News
07.09.19

Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society

Discover this News
05.24.19

Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference

Discover this News
05.15.19

Knopp Biosciences to Present Data on its Potassium Channel Activator Program at 2019 Antiepileptic Drug and Device Trials XV Conference

Discover this News
1 2 3